Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective

In clinical trials, lecanemab and donanemab showed statistically significant yet marginal slowdown of Alzheimer’s disease (AD)-associated cognitive decline. This could be due to their sub-optimal design and/or deployment; alternatively, their limited efficiency could be intrinsic. Distinguishing bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Volloch, Vladimir, Rits-Volloch, Sophia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357217/
https://www.ncbi.nlm.nih.gov/pubmed/37212119
http://dx.doi.org/10.3233/JAD-230164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357217/
https://www.ncbi.nlm.nih.gov/pubmed/37212119
http://dx.doi.org/10.3233/JAD-230164

Ejemplares similares